ArticleDiabetes2018
Insulin Action Research and the Future of Diabetes Treatment: The 2017 Banting Medal for Scientific Achievement Lecture.
Article in Diabetes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 49 citations in OpenAlex.
- Gc inhibition preserves insulin sensitivity and reduces body weight without loss of muscle mass.JCI insight · 2025Article
- Concerted Actions of FoxO1 and PPARα in Hepatic Gene Expression and Metabolic Adaptation.Diabetes · 2025Article
- Uhrf1 downregulation promotes β-cell dedifferentiation by decreasing Foxo1 expression in type 2 diabetes.Journal of diabetes investigation · 2025Article
- Insulin resistance in type 2 diabetes mellitus.Nature reviews. Endocrinology · 2025Review
- The Twin Cycle Hypothesis of type 2 diabetes aetiology: From concept to national NHS programme.Experimental physiology · 2025Review
- A Longitudinal Cohort Assessing the Carotid Intima-Media Thickness Progression and Cardiovascular Risk Factors in a Rural Black South African Community.Journal of clinical medicine · 2025Article
- Single Low-Dose Ionizing Radiation Transiently Enhances Rat RIN-m5F Cell Function via the ROS/p38 MAPK Pathway Without Inducing Cell Damage.Antioxidants (Basel, Switzerland) · 2025Article
- Reepithelialization of Diabetic Skin and Mucosal Wounds Is Rescued by Treatment With Epigenetic Inhibitors.Diabetes · 2024Article
- Reversing pancreatic β-cell dedifferentiation in the treatment of type 2 diabetes.Experimental & molecular medicine · 2023Review
- β Cell function after Roux-en-Y gastric bypass surgery or reduced energy intake alone in people with obesity.JCI insight · 2023Article
- Genetic and pharmacologic inhibition of ALDH1A3 as a treatment of β-cell failure.Nature communications · 2023Article
- Reflections on the state of diabetes research and prospects for treatment.Diabetology international · 2023Review
- Review
- Autotaxin signaling facilitates β cell dedifferentiation and dysfunction induced by Sirtuin 3 deficiency.Molecular metabolism · 2022Article
- Irisin alleviates FFA induced β-cell insulin resistance and inflammatory response through activating PI3K/AKT/FOXO1 signaling pathway.Endocrine · 2022Article
- An integrative transcriptional logic model of hepatic insulin resistance.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Repair of Damaged Pancreatic β Cells: New Hope for a Type 2 Diabetes Reversal?Journal of translational internal medicine · 2021Article
- Role of Insulin in Health and Disease: An Update.International journal of molecular sciences · 2021Review
- A Journey in Diabetes: From Clinical Physiology to Novel Therapeutics: The 2020 Banting Medal for Scientific Achievement Lecture.Diabetes · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Diabetes is caused by combined abnormalities in insulin production and action. The pathophysiology of these defects has been studied extensively and is reasonably well understood. Their causes are elusive and their manifestations pleiotropic, likely reflecting the triple threat of genes, environment, and lifestyle. Treatment, once restricted to monotherapy with secretagogues or insulin, now involves complex combinations of expensive regimens that stem the progression but do not fundamentally alter the underlying causes of the disease. As advances in our understanding of insulin action and β-cell failure reach a critical stage, here I draw on lessons learned from our research on insulin regulation of gene expression and pancreatic β-cell dedifferentiation to address the question of how we can translate this exciting biology into mechanism-based interventions to reverse the course of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.